Santarus News
AbbVie Extends Galapagos Deal - Analyst Blog
Zacks 6:40 AMGLP0634 will now be developed for Crohn's disease as well.
Positive Data on Novo Nordisk's N9-GP - Analyst Blog
Zacks May 21Novo Nordisk recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.
Actavis to Buy Warner Chilcott - Analyst Blog
Zacks May 21The acquisition is expected to be accretive to Actavis' 2014 earnings per share by more than 30%.
JNJ's Simponi Label Expanded - Analyst Blog
Zacks May 21Simponi can now be used for the treatment of moderately to severely active ulcerative colitis in adults.
JNJ's Simponi Label Expanded
May 21FDA Accepts Actavis NDA - Analyst Blog
Zacks May 20A response on the progestin-only transdermal contraceptive patch should be out by Dec 27, 2013.
FDA Accepts Actavis NDA
May 20Requiem for the Bears
May 17If there are any bears left, I hope they aren't trying to short during this bull rampage.
Santarus (SNTS) to Present Additional Data on UCERIS
Street Insider May 17Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting
Business Wire May 17Santarus, Inc. today announced that additional data from two pivotal clinical studies with UCERIS® extended release tablets will be featured in two poster presentations at the Digestive Disease Week® Meeting being held in Orlando, Fla.
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SNTS | 22.53 | +0.23 | +1.03% | 1.463B |
